Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.

NCT Number	NCT07293325
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions	Adults With Simple Obesity
Enrollment	66 participants
Start Date	2025-06-02
Primary Completion	2027-04-02 (estimated)
Study Completion	2027-06-02 (estimated)
Updated on ClinicalTrials.gov	2025-12-19